Investing in a healthy future
Generating superior returns by investing in and building sustainable and leading healthcare businesses
With a Nordic base
Impilo is an investment company focused on investments in Nordic companies operating in the pharmaceutical, medical techonology, healthcare and care services and other health-related industries
Redefining success
Our starting point is that our portfolio companies must contribute to a positive and sustainable development of the societies and markets in which they operate, in order to remain successful in the long-term
Investments
We invest in companies to which we can offer knowledge, capital and new perspectives and thus create momentum to implement change and achieve ambitious goals. Our portfolio consists of market-leading healthcare companies with significant growth potential in the Nordics and beyond.
Our team
Who we are
At Impilo, we are a diverse team with the necessary sector-specific knowledge, experience, and passion to be a responsible and active partner to the companies in which we invest in. We believe that our employees are our most important assets and seek to create a workplace where the team is more important than the individual.
News
KKR and Impilo announce strategic partnership together with management in rare disease platform Immedica Pharma
Stockholm and London, 23 April 2024 – Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.
Impilo invests in Avia Pharma – a leading OTC and Rx pharmaceutical platform
Impilo has closed its investment in Avia Pharma Holding AB, a Sweden-based OTC and Rx pharmaceutical company with presence in the Nordics and Germany. Impilo now partners with two of the co-founders and management of Avia. Our ambition is to build a leading Northern European OTC / Rx platform through organic and inorganic growth.
Loargys® (pegzilarginase) approved in the EU for treatment of arginase 1 deficiency (ARG1-D)
Immedica today announces that the European Commission has granted marketing authorization of Loargys® (pegzilarginase) for the treatment of arginase 1 deficiency (ARG1-D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older. The approval follows the positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use on October 12.
Scantox enters transformational acquisition of QPS Neuropharmacology
Today Scantox, together with its majority owner Impilo, has agreed to acquire the neuropharmacology division of QPS Austria GmbH (“QPS Neuro” or “the Company”) ultimately owned by QPS Holdings LLC. QPS Neuro is a leading drug discovery Contract Research Organization (CRO) that specializes in neurodegenerative, rare diseases and mental disorders.